Minimal residual disease and quality sample evaluation by Next Generation Flow cytometry in multiple myeloma patients: a Brazilian experience

Increasing evidence suggests that of minimal residual disease (MRD) in bone marrow (BM) is one of the most relevant independent prognostic factors in multiple myeloma (MM). Recently, EuroFlow consortium developed and validates the Next Generation Flow cytometry (NGF) approach to evaluate BM MRD in MM patients, at very low levels and, simultaneously is able to estimate the sample hemodilution. Here, we evaluated flow-MRD by NGF in MM patients after autologous stem cell transplantation (ASCT) and compared with conventional techniques for response criteria in serum.